



Attorney's Docket No.: 07917-110001 / (UMMC 00-21) Ho - MT-Rzs

1744#3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Shuk-Mei Ho et al.

Art Unit : 1744

Serial No. : 10/033,024

Examiner : Unknown

Filed : October 31, 2001

Title : APOPTOSIS-INDUCING RIBOZYMES

Commissioner for Patents

Washington, D.C. 20231

RECEIVED
APR 25 2002
TC 1700

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the attached form PTO-1449, copies of which are enclosed.

This statement is being filed before the receipt of a first Office action on the merits. Please apply any charges or credits to Deposit Account No. 06-1050, referencing attorney docket number 07917-110001.

Respectfully submitted,

Date:

April 16, 2002

J. Peter Fasse
J. Peter Fasse
Reg. No. 32,983

Fish & Richardson P.C.
225 Franklin Street
Boston, Massachusetts 02110-2804
Telephone: (617) 542-5070
Facsimile: (617) 542-8906

20393296.doc

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Date of Deposit


April 16, 2002

Signature

Kimberly A. Hutchins

Typed or Printed Name of Person Signing Certificate

Kimberly A. Hutchins



Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07917-110001	Application No. 10/033,021
	Applicant Shuk-Mei Ho et al.		
	Filing Date October 31, 2001	Group Art. Unit	

RECEIVED
APR 25 2002
16 1700

U.S. Patent Documents							
Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	6,057,299	05/02/2000	Henderson			
	AB	5,116,742	05/26/1992	Cech et al.			
	AC	5,093,246	03/03/1992	Cech et al.			

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AD							

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AE	Amarzguioi et al., "Hammerhead ribozyme design and application" <i>Cell. Mol. Life Sci.</i> 54(11):1175-1202 (1998)
	AF	Chang et al., "Interaction between prostatic fibroblast and epithelial cells in culture: role of androgen" <i>Endocrinology</i> 125(5):2719-2727 (1989)
	AG	Chung et al., "Use of L-plastin promoter to develop an adenoviral system that confers transgene expression in ovarian cancer cells but not in normal mesothelial cells" <i>Cancer Gene Therapy</i> 6(2):99-106 (1999)
	AH	De-Chao et al., "Identification of the Transcriptional Regulatory Sequences of Human Kallikrein 2 and Their Use in the Construction of Calydon Virus 764, an Attenuated Replication Competent Adenovirus for Prostate Cancer Therapy" <i>Cancer Research</i> 59:1498-1504 (1999)
	AI	Dorai et al., "Development of a hammerhead ribozyme against bcl-2.I. Preliminary evaluation of a potential gene therapeutic agent for hormone-refractory human prostate cancer" <i>Prostate</i> 32(4):246-258 (1997)
	AJ	Ebert et al., "Expression of metallothionein II in intestinal metaplasia, dysplasia, and gastric cancer" <i>Cancer Res.</i> 60(7):1995-2001 (2000)
	AK	Haselhoff et al., "Simple RNA enzymes with new and highly specific endoribonuclease activities" <i>Nature</i> 334:585-591 (1988)
	AL	Karin et al., "Human metallothionein genes: molecular cloning and sequence analysis of the mRNA" <i>Nucleic Acids Res.</i> 10(10):3165-3173 (1982)
	AM	Latham et al., "Prostate-specific Antigen Promoter/Enhancer Driven Gene Therapy for Prostate Cancer: Construction and Testing of a Tissue-specific Adenovirus Vector" <i>Cancer Research</i> 60:334-341 (2000)
	AN	Lee et al., "Hammerhead ribozymes mediated down-regulation of rat metallothionein mRNAs expression" <i>Advances in Life Sciences</i> 273-280 (1999)
	AO	Lee et al., "Generation and Characterization of Hammerhead Ribozymes Targeting Rodent Metallothionein-I and -II Ribonucleic Acid" <i>Toxicol. Appl. Pharmacol.</i> 161:294-301 (1999)
	AP	Lu et al., "Transcriptionally regulated adenoviruses for prostate-specific gene therapy" <i>World J Urol.</i> 18:93-101 (2000)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

APR 22 2002

Sheet 2 of 2

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07917-110001	Application No. 10/033,024
	Applicant Shuk-Mei Ho et al.		
	Filing Date October 31, 2001	Group Art Unit	

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AQ	Marples et al., "Development of synthetic promoters for radiation-mediated gene therapy" <i>Gene Therapy</i> 7:511-517 (2000)
	AR	Norris et al., "Design and testing of ribozymes for cancer gene therapy" <i>Cancer Gene Therapy: Past Achievements and Future Challenges</i> 465:293-301 (2000)
	AS	Steiner et al., "In vivo expression of prostate-specific adenoviral vectors in a canine model" <i>Cancer Gene Therapy</i> 6(5):456-464 (1999)
	AT	Werner et al., "The effect of base mismatches in the substrate recognition helices of hammerhead ribozymes on binding and catalysis" <i>Nucleic Acids Res.</i> 23:2092-2096 (1995)
	AU	
	AV	

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)